The Drug Users Bible [Extended Edition]
Subtitle: Harm Reduction, Risk Mitigation, Personal Safety
Publisher: MxZero Publishing
Published: 2022
Place of publication: UK
Format: Paperback; PDF
Number of pages: 638
ISBN-13: 9780995593695
Copyright date: 2022 MxZero Publishing
First sentence: Psychoactive substances are generally considered to be materials that alter
perception, mood or consciousness. However, the context of their use far exceeds
that of recreation. As entheogens, many are used for ritual, spiritual, or shamanic
purposes, and are immersed in history. Others are used to explore new insights and
engineer different perspectives, both for personal development, nootropic, and
academic purposes.
This book embraces all of these dimensions. It charts and examines the entire
drugscape, which was investigated and researched during a time of unparalleled
access to psychoactive materials of all types and classes.
Table of contents: title: Table of Contents; title: 1. DRUGSCAPE: AN INTRODUCTION; title: 1.1 Safety First; title: 1.1.1 The 10 Commandments; title: 1.1.2 How To Use A Drug Testing Kit; title: 1.2 Interpreting the Reports; title: 1.2.1 Definition of Terms; title: 1.2.2 The Shulgin Rating Scale; title: 1.2.3 Classification; title: 1.2.4 Routes of Administration (RoA); title: 1.2.5 More On Source & Jurisdiction; title: 1.3 General Safety Notes; title: 1.3.1 If You Are Not An Adult; title: 1.3.2 Risk Mitigation For IV; title: 1.3.3 Nasal Care; title: 1.3.4 Chemsex; title: 1.3.5 What Goes Up Must Come Down; title: 1.3.6 Complacency Kills; title: 2. CHEMSCAPE: A CHEMICAL JOURNEY; title: 2.1 Introduction; title: 2.2 Psychedelics; title: 2.2.1 1P-LSD; title: 2.2.2 1cP-LSD; title: 2.2.3 1P-ETH-LAD; title: 2.2.4 2C-B; title: 2.2.5 2C-B-AN; title: 2.2.6 2C-B-FLY; title: 2.2.7 2C-E; title: 2.2.8 2C-I; title: 2.2.9 4-ACO-DMT; title: 2.2.10 4-HO-MET; title: 2.2.11 5-MeO-DALT; title: 2.2.12 5-MeO-DIBF; title: 2.2.13 AL-LAD; title: 2.2.14 AMT; title: 2.2.15 BK-2C-B; title: 2.2.16 Changa; title: 2.2.17 DMT; title: 2.2.18 DOM; title: 2.2.19 LSD; title: 2.2.20 LSZ; title: 2.2.21 TMA; title: 2.3 Stimulants; title: 2.3.1 2AI; title: 2.3.2 3,4 CTMP; title: 2.3.3 3-FPM; title: 2.3.4 3-MMC; title: 2.3.5 4-FA; title: 2.3.6 4-Me-TMP; title: 2.3.7 4F-EPH; title: 2.3.8 4F-MPH; title: 2.3.9 Adderall; title: 2.3.10 Amphetamine; title: 2.3.11 a-PHP; title: 2.3.12 Caffeine; title: 2.3.13 Cocaine; title: 2.3.14 EPH; title: 2.3.15 HDMP-28; title: 2.3.16 Hexen; title: 2.3.17 IPPH; title: 2.3.18 Methamphetamine; title: 2.3.19 Methylphenidate; title: 2.3.20 MPA; title: 2.3.21 NM2AI; title: 2.3.22 PPH; title: 2.3.23 Pipradrol; title: 2.3.24 TPA; title: 2.4 Anxiolytics & Sedatives; title: 2.4.1 Alprazolam; title: 2.4.2 Carisoprodol; title: 2.4.3 Clonazolam; title: 2.4.4 Diazepam; title: 2.4.5 Etizolam; title: 2.4.6 Gabapentin; title: 2.4.7 Pregabalin; title: 2.4.8 Pyrazolam; title: 2.4.9 Zopiclone; title: 2.4.10 Others; title: 2.5 Intoxicating Depressants; title: 2.5.1 Alcohol; title: 2.5.2 Codeine; title: 2.5.3 Fentanyl; title: 2.5.4 GHB; title: 2.5.5 Heroin; title: 2.5.6 Lean; title: 2.5.7 Morphine; title: 2.5.8 Oxycodone; title: 2.5.9 Poppers; title: 2.5.10 Sentia; title: 2.5.11 Tramadol; title: 2.6 Dissociatives; title: 2.6.1 3-Ho-PCP; title: 2.6.2 3-MeO-PCMo; title: 2.6.3 Diphenidine; title: 2.6.4 DXM; title: 2.6.5 Ephenidine; title: 2.6.6 Ketamine; title: 2.6.7 Mefloquine; title: 2.6.8 MXE; title: 2.6.9 MXP; title: 2.6.10 N2O; title: 2.7 Empathogens & Entactogens; title: 2.7.1 6-APB; title: 2.7.2 MDA; title: 2.7.3 MDAI; title: 2.7.4 MDMA; title: 2.7.5 MEAI; title: 2.7.6 Mephedrone; title: 2.7.7 Methylone; title: 2.7.8 MNA; title: 2.7.9 Mexedrone; title: 2.8 Synthetic Cannabinoids; title: 2.8.1 5F-AKB48; title: 2.8.2 AM-2201; title: 2.8.3 AM-694; title: 2.8.4 JWH-018; title: 2.8.5 JWH-073; title: 2.9 Nootropics; title: 2.9.1 5-HTP; title: 2.9.2 Aniracetam + Citicoline; title: 2.9.3 Armodafinil; title: 2.9.4 L-Theanine; title: 2.9.5 Modafiendz; title: 2.9.6 Modafinil; title: 2.9.7 Noopept; title: 2.9.8 NSI 189; title: 2.9.9 Phenibut; title: 2.9.10 Picamilon; title: 2.9.11 PRL-8-53; title: 3. BOTSCAPE: A BOTANICAL JOURNEY; title: 3.1 Introduction; title: 3.2 Psychedelics; title: 3.2.1 Ayahuasca; title: 3.2.2 Cebil; title: 3.2.3 Chaliponga Leaves; title: 3.2.4 Fly Agaric; title: 3.2.5 HBWS; title: 3.2.6 Iboga; title: 3.2.7 Magic Mushrooms; title: 3.2.8 Magic Truffles; title: 3.2.9 Morning Glory Seeds; title: 3.2.10 Ololiuqui; title: 3.2.11 Salvia; title: 3.2.12 Sananga; title: 3.2.13 San Pedro Cactus; title: 3.2.14 Sensory Deprivation; title: 3.2.15 Shirodhara; title: 3.2.16 Sinicuichi; title: 3.2.17 Syrian Rue; title: 3.2.18 Yopo; title: 3.3 Stimulants; title: 3.3.1 Betel Nut; title: 3.3.2 Coca; title: 3.3.3 Ephedra; title: 3.3.4 Ginseng; title: 3.3.5 Green Tea; title: 3.3.6 Guarana; title: 3.3.7 Guayusa; title: 3.3.8 Horny Goat Weed; title: 3.3.9 Khaini; title: 3.3.10 Kola Nut; title: 3.3.11 Wormwood; title: 3.3.12 Yerba Mate; title: 3.3.13 Yohimbe; title: 3.4 Sedatives; title: 3.4.1 Blue Lotus; title: [Pink Lotus Flower, Red Lily]; title: 3.4.2 Cacao; title: 3.4.3 Catnip; title: 3.4.4 Chamomile; title: 3.4.5 Damiana; title: 3.4.6 Frankincense; title: 3.4.7 Hops; title: 3.4.8 Imphepho; title: 3.4.9 Indian Warrior; title: 3.4.10 Kanna; title: 3.4.11 Lavender; title: 3.4.12 Maconha Brava; title: 3.4.13 Marihuanilla; title: 3.4.14 Mullein; title: 3.4.15 Mulungu; title: 3.4.16 Passion Flower; title: 3.4.17 Rhodiola; title: 3.4.18 Saffron; title: 3.4.19 St. John's Wort; title: 3.4.20 Skullcap; title: 3.4.21 Valerian Root; title: 3.4.22 White Sage; title: 3.4.23 Wild Dagga; title: 3.4.24 Wild Lettuce; title: 3.5 Nootropics; title: 3.5.1 Catuaba; title: 3.5.2 Celastrus Paniculatus; title: 3.5.3 Ginkgo; title: 3.6 Oneirogens; title: 3.6.1 Calea; title: 3.6.2 Entada Rheedii; title: 3.6.3 Mexican Tarragon; title: 3.6.4 Mugwort; title: 3.6.5 Ubulawu; title: 3.7 Deliriants; title: 3.7.1 Datura; title: 3.7.2 Nutmeg; title: 3.8 Unclassified; title: 3.8.1 Cannabis; title: 3.8.2 Essential Oils; title: 3.8.3 Kava Kava; title: 3.8.4 Kratom; title: 3.8.5 Mad Honey; title: 3.8.6 Mapacho; title: 3.8.7 Opium; title: 3.8.8 Rapé; title: 3.8.9 Sakae Naa; title: 3.8.10 Tobacco; title: 4. WORLDSCAPE: THE WIDER CONTEXT; title: 4.1 How Many People Use Drugs?; title: 4.2 The Relative Harm; title: 4.3 Addiction & Overdose; title: 4.3.1 Addiction; title: 4.3.2 If You Are Addicted; title: 4.3.3 Alcoholism; title: 4.3.4 Overdose & Emergency Response; title: 4.3.5 Drug Related Deaths: Notable People; title: 4.4 The LawScape; title: 4.4.1 The United Kingdom; title: 4.4.2 The United States; title: 4.4.3 The Rest of The World; title: 4.4.4 Dealers: A Different Perspective; title: 4.4.5 The Role of The Media; title: 4.4.6 Mandatory Drug Testing; title: 4.4.7 Activism: The Charter of Drug Users Rights; title: 4.5 Drug Tourism; title: 4.5.1 The Dutch Connection; title: 4.5.2 Global Snapshots; title: 4.6 Culture & Society (Reference); title: 4.6.1 Art, Film, Literature, Music; title: 4.6.2 Food For The Psychedelic Mind; title: 4.6.3 Books & Reference; title: 4.7 Confessions of a Lab Rat; title: 4.7.1 Q&A; title: 4.7.2 About The Author – In His Own Words; title: 4.8 Argot; title: 4.8.1 Idioms & Acronyms; title: 4.8.2 Common, Street & Brand Names; title: 4.8.3 Poly Drug Combinations; title: 4.8.4 Selected Molecules; title: 4.8.5 Alphabetical Index; title: 4.9 Internet Resources; title: 4.9.1 Harm Reduction & Safety; title: 4.9.2 The Drug Users Bible; title: 4.10 Supplementary Notes; title: 4.11 Supplementary Photographs; title: 4.12 Namaste: A Final Note; title: Epilogue & The Last Word